NASDAQ:ACRX AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News $1.03 -0.06 (-5.50%) (As of 05:11 PM ET) Add Compare Share Share Today's Range$1.03▼$1.1450-Day Range$0.60▼$1.1152-Week Range$0.55▼$7.60Volume33,520 shsAverage Volume194,367 shsMarket Capitalization$11.25 millionP/E Ratio0.15Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability AcelRx Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy7.08% of Float Sold ShortDividend StrengthN/ASustainability-2.41Upright™ Environmental ScoreNews Sentiment0.58Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.67) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector436th out of 983 stocksPharmaceutical Preparations Industry210th out of 486 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for AcelRx Pharmaceuticals. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.08% of the float of AcelRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcelRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AcelRx Pharmaceuticals has recently decreased by 10.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcelRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcelRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for AcelRx Pharmaceuticals is -2.41. Previous Next 2.5 News and Social Media Coverage News SentimentAcelRx Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AcelRx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest10 people have searched for ACRX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of AcelRx Pharmaceuticals is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AcelRx Pharmaceuticals is 0.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.68.Price to Earnings Ratio vs. SectorThe P/E ratio of AcelRx Pharmaceuticals is 0.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.39.Price to Book Value per Share RatioAcelRx Pharmaceuticals has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AcelRx Pharmaceuticals (NASDAQ:ACRX) StockAcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.Read More Receive ACRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRX Stock News HeadlinesMay 31, 2023 | americanbankingnews.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Short Interest UpdateMay 30, 2023 | americanbankingnews.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Sees Significant Drop in Short InterestJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 17, 2023 | americanbankingnews.comAcelRx Pharmaceuticals, Inc. to Post Q2 2023 Earnings of ($0.53) Per Share, HC Wainwright Forecasts (NASDAQ:ACRX)May 13, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 12, 2023 | americanbankingnews.comAcelRx Pharmaceuticals (NASDAQ:ACRX) Rating Lowered to Sell at StockNews.comMay 11, 2023 | msn.comRecap: AcelRx Pharmaceuticals Q1 EarningsMay 10, 2023 | finance.yahoo.comAcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1June 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 10, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | americanbankingnews.comAcelRx Pharmaceuticals (ACRX) to Release Earnings on WednesdayMay 4, 2023 | finance.yahoo.comEarnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to DeclineMay 3, 2023 | msn.comAcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseApril 27, 2023 | finance.yahoo.comAcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023April 19, 2023 | americanbankingnews.comShort Interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Expands By 17.5%April 8, 2023 | americanbankingnews.comAcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded by StockNews.com to HoldApril 5, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora PharmaceuticalsApril 4, 2023 | finance.yahoo.comAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call TranscriptMarch 31, 2023 | finanznachrichten.deAcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate UpdateMarch 31, 2023 | markets.businessinsider.comAcelrx (ACRX) Receives a Hold from H.C. WainwrightMarch 30, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate UpdateMarch 29, 2023 | msn.comEarnings Outlook For AcelRx PharmaceuticalsMarch 29, 2023 | americanbankingnews.comAcelRx Pharmaceuticals (ACRX) Set to Announce Earnings on ThursdayMarch 21, 2023 | finance.yahoo.comAcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023March 14, 2023 | marketwatch.comAcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRXMarch 14, 2023 | msn.comAcelRx adds 16% on plans to divest pain therapyMarch 14, 2023 | finance.yahoo.comAcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora PharmaceuticalsSee More Headlines ACRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRX Company Calendar Last Earnings3/30/2023Today6/02/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRX CUSIPN/A CIK1427925 Webwww.acelrx.com Phone(650) 216-3500Fax650-216-6500Employees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$6.91 Trailing P/E Ratio0.16 Forward P/E RatioN/A P/E GrowthN/ANet Income$47.76 million Net Margins2,696.50% Pretax Margin3,946.35% Return on Equity-93.99% Return on Assets-50.85% Debt Debt-to-Equity RatioN/A Current Ratio1.83 Quick Ratio1.83 Sales & Book Value Annual Sales$1.77 million Price / Sales6.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book0.84Miscellaneous Outstanding Shares10,920,000Free Float10,312,000Market Cap$11.90 million OptionableOptionable Beta0.25 Key ExecutivesVincent J. AngottiPresident, Chief Executive Officer & DirectorRaffi AsadorianChief Financial & Accounting OfficerPamela Pierce PalmerDirector & Chief Medical OfficerBadri N. DasuChief Engineering OfficerMark A. EvashenkVice President-Clinical OperationsKey CompetitorsCelyad OncologyNASDAQ:CYADLipella PharmaceuticalsNASDAQ:LIPOCingulateNASDAQ:CINGAptorum GroupNASDAQ:APMBright Minds BiosciencesNASDAQ:DRUGView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 40,482 shares on 5/12/2023Ownership: 0.371%Group One Trading L.P.Bought 1,800 shares on 5/12/2023Ownership: 0.000%Simplex Trading LLCBought 10,000 shares on 4/27/2023Ownership: 0.000%Vincent J AngottiBought 46,400 shares on 6/7/2022Total: $10,208.00 ($0.22/share)View All Insider TransactionsView All Institutional Transactions ACRX Stock - Frequently Asked Questions How have ACRX shares performed in 2023? AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 51.8% and is now trading at $1.09. View the best growth stocks for 2023 here. Are investors shorting AcelRx Pharmaceuticals? AcelRx Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 765,800 shares, a drop of 10.5% from the April 30th total of 855,800 shares. Based on an average trading volume of 204,900 shares, the days-to-cover ratio is currently 3.7 days. Approximately 7.1% of the company's shares are sold short. View AcelRx Pharmaceuticals' Short Interest. When is AcelRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ACRX earnings forecast. How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings data on Thursday, March, 30th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.90. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 93.99%. When did AcelRx Pharmaceuticals' stock split? AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of AcelRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA). What is AcelRx Pharmaceuticals' stock symbol? AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX." Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian Adams and Vincent J Angotti. View institutional ownership trends. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AcelRx Pharmaceuticals' stock price today? One share of ACRX stock can currently be purchased for approximately $1.09. How much money does AcelRx Pharmaceuticals make? AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $11.90 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or $6.91 on an earnings per share basis. How can I contact AcelRx Pharmaceuticals? AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500. This page (NASDAQ:ACRX) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AcelRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.